Table 1.

Patient characteristics.

No.	Age range	BMI	Years MS	Previous treatment	ARR prev. year	Baseline EDSS
1	30–34	20.2	12	Natalizumab	1	3.0
2	40–44	21.7	13	Glatirameracetat	3	3.0
3	45–49	20.0	1	β-1b-Interferon	1	2.0
4	45–49	26.9	6	β-1a-Interferon	1	2.0
5	40–44	30.5	10	Natalizumab	3	5.0
6	45–49	22.3	14	no	4	4.5
7	40–44	22.9	0	no	2	1.5
8	40–44	29.0	19	Natalizumab	3	2.5
9	25–29	20.3	10	β-1a-Interferon	0	2.5
10	25–29	18.4	10	β-1a-Interferon	1	6.0
11	25–29	20.5	3	β-1a-Interferon	2	3.5
12	40–44	32.3	3	Glatirameracetat	1	1.5
13	30–34	25.7	1	Glatirameracetat	0	3.0
14	40–44	27.2	9	β-1a-Interferon	1	2.5
15	40–44	22.8	2	no	2	4.0
16	25–29	13.2	3	β-1a-Interferon	3	2.0
17	50–54	21.0	5	β-1a-Interferon	3	4.5
18	40–44	26.5	1	β-1a-Interferon	0	2.0
19	40–44	29.4	9	β-1b-Interferon	1	2.0
20	40–44	29.7	2	no	1	2.0

Characteristics of evaluated MS patients including age range (years), body mass index (BMI, kg/m²), years since MS diagnosis was met (years MS), previous treatment, annual relapse rate 12 months before baseline (ARR prev. year) and expanded disability status score (Baseline EDSS) at baseline (n = 20).